1.Arboix A. Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. World J Clin Cases. 2015;3(5):418–29.
2.Griesenauer B, Paczesny S. The ST2/IL–33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017;8:475.
3.Dattagupta A, Immaneni S. ST2: Current status. Indian Heart J. 2018;70 Suppl 1:S96-S101.
4.Aimo A, Migliorini P, Vergaro G, Franzini M, Passino C, Maisel A, et al. The IL–33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? Int J Cardiol. 2018;267:188–92.
5.Altara R, Ghali R, Mallat Z, Cataliotti A, Booz GW, Zouein FA. Conflicting vascular and metabolic impact of the IL–33/sST2 axis. Cardiovascular research. 2018;114(12):1578–94.
6.Vilchez JA, Perez-Cuellar M, Marin F, Gallego P, Manzano-Fernandez S, Valdes M, et al. sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. Eur J Clin Invest. 2015;45(9):899–905.
7.Andersson C, Preis SR, Beiser A, DeCarli C, Wollert KC, Wang TJ, et al. Associations of Circulating Growth Differentiation Factor–15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke. Stroke. 2015;46(9):2568–75.
8.Korhonen P, Kanninen KM, Lehtonen S, Lemarchant S, Puttonen KA, Oksanen M, et al. Immunomodulation by interleukin–33 is protective in stroke through modulation of inflammation. Brain Behav Immun. 2015;49:322–36.
9.Wolcott Z, Batra A, Bevers MB, Sastre C, Khoury J, Sperling M, et al. Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke. Ann Clin Transl Neurol. 2017;4(8):553–63.
10.Dieplinger B, Bocksrucker C, Egger M, Eggers C, Haltmayer M, Mueller T. Prognostic Value of Inflammatory and Cardiovascular Biomarkers for Prediction of 90-Day All-Cause Mortality after Acute Ischemic Stroke-Results from the Linz Stroke Unit Study. Clinical chemistry. 2017;63(6):1101–9.
11.Song B, Fang H, Zhao L, Gao Y, Tan S, Lu J, et al. Validation of the ABCD3-I score to predict stroke risk after transient ischemic attack. Stroke. 2013;44(5):1244–8.
12.Zhao L, Wang R, Song B, Tan S, Gao Y, Fang H, et al. Association between atherogenic dyslipidemia and recurrent stroke risk in patients with different subtypes of ischemic stroke. Int J Stroke. 2015;10(5):752–8.
13.Song B, Hu R, Pei L, Cao Y, Chen P, Sun S, et al. Dual antiplatelet therapy reduced stroke risk in high-risk patients with transient ischaemic attack assessed by ABCD3-I score. Eur J Neurol. 2019;26(4):610–6.
14.Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276–93.
15.Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19(12):1497–500.
16.Fischer U, Baumgartner A, Arnold M, Nedeltchev K, Gralla J, De Marchis GM, et al. What is a minor stroke? Stroke. 2010;41(4):661–6.
17.Luo Y, Zhou Y, Xiao W, Liang Z, Dai J, Weng X, et al. Interleukin–33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain research. 2015;1597:86–94.
18.Yang Y, Liu H, Zhang H, Ye Q, Wang J, Yang B, et al. ST2/IL–33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2017;37(18):4692–704.
19.Du LX, Wang YQ, Hua GQ, Mi WL. IL–33/ST2 Pathway as a Rational Therapeutic Target for CNS Diseases. Neuroscience. 2018;369:222–30.
20.Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL–33/IL–31 Axis: A Potential Inflammatory Pathway. Mediators of inflammation. 2018;2018:3858032.
21.Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. The American journal of cardiology. 2015;115(7 Suppl):3b–7b.
22.Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, Hoetzenecker K, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovascular research. 2010;87(4):769–77.
23.Chen W, Lin A, Yu Y, Zhang L, Yang G, Hu H, et al. Serum Soluble ST2 as a Novel Inflammatory Marker in Acute Ischemic Stroke. Clin Lab. 2018;64(9):1349–56.
24.Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation Heart failure. 2011;4(2):180–7.
25.Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936–44.
26.Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clinical chemistry. 2012;58(12):1673–81.
27.Ates I, Ozkayar N, Ates H, Karakulak UN, Kursun O, Topcuoglu C, et al. Elevated circulating sST2 associated with subclinical atherosclerosis in newly diagnosed primary hypertension. Hypertension research: official journal of the Japanese Society of Hypertension. 2016;39(7):513–8.
28.Ma X, Yuan H, Luan HX, Shi YL, Zeng XL, Wang Y. Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation. Clinica chimica acta; international journal of clinical chemistry. 2018;480:138–42.
29.Dieplinger B, Egger M, Haltmayer M, Kleber ME, Scharnagl H, Silbernagel G, et al. Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clinical chemistry. 2014;60(3):530–40.